Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease

Kidney International

Volumn 90, Issue 1, 2016, Pages 77-89

  Carrillo López, Natalia ^a   Panizo, Sara ^a   Alonso Montes, Cristina ^a   Román García, Pablo ^a   Rodríguez, Isabel ^a   Martínez Salgado, Carlos ^b   Dusso, Adriana S ^a   Naves, Manuel ^a   Cannata Andía, Jorge B ^a,c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

Author keywords

bone; chronic kidney disease; FGF23; hyperparathyroidism; phosphate; uremia

Indexed keywords

BETA CATENIN; CALCIUM; CATHEPSIN K; CREATININE; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSCRIPTION FACTOR RUNX2; WNT PROTEIN; BETA GLUCURONIDASE; BIOLOGICAL MARKER; CTSK PROTEIN, RAT; DICKKOPF-1 PROTEIN, RAT; FIBROBLAST GROWTH FACTOR; MEMBRANE PROTEIN; PHOSPHATE INTAKE; RUNX2 PROTEIN, RAT; SFRP1 PROTEIN, RAT; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BONE ATROPHY; BONE DENSITY; CALCIUM BLOOD LEVEL; CATHEPSIN K GENE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVATION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOCALCIN GENE; PARACRINE SIGNALING; PHOSPHATE BLOOD LEVEL; POROSITY; PRIORITY JOURNAL; RAT; RUNX2 GENE; SIGNAL TRANSDUCTION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BONE MINERALIZATION; CHRONIC KIDNEY FAILURE; COMPLICATION; DECALCIFICATION, PATHOLOGIC; DISEASE MODEL; DRUG EFFECTS; HUMAN; METABOLISM; OSTEOBLAST; PATHOLOGY; PHOSPHATE INTAKE; TIBIA; TUMOR CELL LINE; UREMIA; WISTAR RAT; WNT SIGNALING;

ANIMALS; BETA CATENIN; BIOMARKERS; CALCIFICATION, PHYSIOLOGIC; CALCIUM; CATHEPSIN K; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DECALCIFICATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; OSTEOBLASTS; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; PHOSPHORUS, DIETARY; POROSITY; RATS; RATS, WISTAR; RENAL INSUFFICIENCY, CHRONIC; TIBIA; UREMIA; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84988419379     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.01.024     Document Type: Article

References (63)

1. 1 Moe, S., Drueke, T., Cunningham, J., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69 (2006), 1945–1953.
2. 2 Moe, S.M., Chen, N.X., Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95 (2004), 560–567.
3. 3 Moe, S.M., Chen, N.X., Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19 (2008), 213–216.
4. 4 Monroe, D.G., McGee-Lawrence, M.E., Oursler, M.J., et al. Update on Wnt signaling in bone cell biology and bone disease. Gene 492 (2012), 1–18.
5. 5 Westendorf, J.J., Kahler, R.A., Schroeder, T.M., Wnt signaling in osteoblasts and bone diseases. Gene 341 (2004), 19–39.
6. 6 Lopez-Hilker, S., Dusso, A.S., Rapp, N.S., et al. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 259 (1990), F432–F437.
7. 7 Slatopolsky, E., Brown, A., Dusso, A., Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73 (1999), S14–S19.
8. 8 Rix, M., Andreassen, H., Eskildsen, P., et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56 (1999), 1084–1093.
9. 9 Lips, P., Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22 (2001), 477–501.
10. 10 Bilezikian, J.P., Bone strength in primary hyperparathyroidism. Osteoporos Int 14:suppl 5 (2003), S113–S115 [discussion: S115–S117].
11. 11 Huttunen, M.M., Tillman, I., Viljakainen, H.T., et al. High dietary phosphate intake reduces bone strength in the growing rat skeleton. J Bone Miner Res 22 (2007), 83–92.
12. 12 Kemi, V.E., Karkkainen, M.U., Lamberg-Allardt, C.J., High phosphorus intakes acutely and negatively affect Ca and bone metabolism in a dose-dependent manner in healthy young females. Br J Nutr 96 (2006), 545–552.
13. 13 Cejka, D., Herberth, J., Branscum, A.J., et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 6 (2011), 877–882.
14. 14 Evenepoel, P., D'Haese, P., Brandenburg, V., Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 88 (2015), 235–240.
15. 15 Baron, R., Kneissel, M., WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19 (2013), 179–192.
16. 16 Krishnan, V., Bryant, H.U., Macdougald, O.A., Regulation of bone mass by Wnt signaling. J Clin Invest 116 (2006), 1202–1209.
17. 17 Bennett, C.N., Longo, K.A., Wright, W.S., et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 102 (2005), 3324–3329.
18. 18 Gaur, T., Lengner, C.J., Hovhannisyan, H., et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280 (2005), 33132–33140.
19. 19 Bodine, P.V., Billiard, J., Moran, R.A., et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 96 (2005), 1212–1230.
20. 20 McClung, M.R., Grauer, A., Boonen, S., et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370 (2014), 412–420.
21. 21 Recker, R.R., Benson, C.T., Matsumoto, T., et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30 (2015), 216–224.
22. 22 Padhi, D., Jang, G., Stouch, B., et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26 (2011), 19–26.
23. 23 Fang, Y., Ginsberg, C., Seifert, M., et al. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 25 (2014), 1760–1773.
24. 24 Pozzi, S., Fulciniti, M., Yan, H., et al. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone 53 (2013), 487–496.
25. 25 Moyses, R.M., Schiavi, S.C., Sclerostin, osteocytes, and chronic kidney disease – mineral bone disorder. Semin Dial 28 (2015), 578–586.
26. 26 Liu, S., Song, W., Boulanger, J.H., et al. Role of TGF-beta in a mouse model of high turnover renal osteodystrophy. J Bone Miner Res 29 (2014), 1141–1157.
27. 27 Sabbagh, Y., Graciolli, F.G., O'Brien, S., et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27 (2012), 1757–1772.
28. 28 Shimada, T., Kakitani, M., Yamazaki, Y., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 (2004), 561–568.
29. 29 Ben-Dov, I.Z., Galitzer, H., Lavi-Moshayoff, V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117 (2007), 4003–4008.
30. 30 Hu, M.C., Shi, M., Zhang, J., et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22 (2011), 124–136.
31. 31 Lindberg, K., Amin, R., Moe, O.W., et al. The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol 25 (2014), 2169–2175.
32. 32 Hu, M.C., Shi, M., Zhang, J., et al. Renal production, uptake, and handling of circulating αKlotho. J Am Soc Nephrol 27 (2016), 79–90.
33. 33 Hu, M.C., Shi, M., Cho, H.J., et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 26 (2015), 1290–1302.
34. 34 Lin, G.L., Hankenson, K.D., Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J Cell Biochem 112 (2011), 3491–3501.
35. 35 Moe, S.M., Chen, N.X., Newman, C.L., et al. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res 30 (2015), 499–509.
36. 36 Claes, K.J., Viaene, L., Heye, S., et al. Sclerostin: another vascular calcification inhibitor?. J Clin Endocrinol Metab 98 (2013), 3221–3228.
37. 37 Fang, Y., Ginsberg, C., Sugatani, T., et al. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 85 (2014), 142–150.
38. 38 He, W., Dai, C., Li, Y., et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 20 (2009), 765–776.
39. 39 Bellido, T., Ali, A.A., Gubrij, I., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146 (2005), 4577–4583.
40. 40 Kulkarni, N.H., Halladay, D.L., Miles, R.R., et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95 (2005), 1178–1190.
41. 41 Guo, J., Liu, M., Yang, D., et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab 11 (2010), 161–171.
42. 42 Olauson, H., Lindberg, K., Amin, R., et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet, 9, 2013, e1003975.
43. 43 Faul, C., Amaral, A.P., Oskouei, B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 121 (2011), 4393–4408.
44. 44 Shalhoub, V., Ward, S.C., Sun, B., et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int 89 (2011), 140–150.
45. 45 Glinka, A., Wu, W., Delius, H., et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391 (1998), 357–362.
46. 46 Aguilera, O., Gonzalez-Sancho, J.M., Zazo, S., et al. Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer. Oncotarget 6 (2015), 5903–5917.
47. 47 Heijboer, A.C., Blankenstein, M.A., Hoenderop, J., et al. Laboratory aspects of circulating alpha-Klotho. Nephrol Dial Transplant 28 (2013), 2283–2287.
48. 48 Voormolen, N., Noordzij, M., Grootendorst, D.C., et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 22 (2007), 2909–2916.
49. 49 Roman-Garcia, P., Carrillo-Lopez, N., Fernandez-Martin, J.L., et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 46 (2010), 121–128.
50. 50 Drechsler, C., Evenepoel, P., Vervloet, M.G., et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30 (2015), 288–293.
51. 51 Viaene, L., Behets, G.J., Claes, K., et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?. Nephrol Dial Transplant 28 (2013), 3024–3030.
52. 52 Ormrod, D., Miller, T., Experimental uremia. Description of a model producing varying degrees of stable uremia. Nephron 26 (1980), 249–254.
53. 53 Meir, T., Durlacher, K., Pan, Z., et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int 86 (2014), 1106–1115.
54. 54 Lavi-Moshayoff, V., Wasserman, G., Meir, T., et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299 (2010), F882–F889.
55. 55 Hong, S.H., Lu, X., Nanes, M.S., et al. Regulation of osterix (Osx, Sp7) and the Osx promoter by parathyroid hormone in osteoblasts. J Mol Endocrinol 43 (2009), 197–207.
56. 56 Gomez-Alonso, C., Menendez-Rodriguez, P., Virgos-Soriano, M.J., et al. Aluminum-induced osteogenesis in osteopenic rats with normal renal function. Calcif Tissue Int 64 (1999), 534–541.
57. 57 Naves-Diaz, M., Carrillo-Lopez, N., Rodriguez-Rodriguez, A., et al. Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency. Menopause 17 (2010), 766–771.
58. 58 Parfitt, A.M., Bone histomorphometry: standardization of nomenclature, symbols and units. Summary of proposed system. Bone Miner 4 (1988), 1–5.
59. 59 Erben, R.G., Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem 45 (1997), 307–313.
60. 60 Roman-Garcia, P., Quiros-Gonzalez, I., Mottram, L., et al. Vitamin B(1)(2)-dependent taurine synthesis regulates growth and bone mass. J Clin Invest 124 (2014), 2988–3002.
61. 61 Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001), 402–408.
62. 62 Carrillo-Lopez, N., Alvarez-Hernandez, D., Gonzalez-Suarez, I., et al. Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrol Dial Transplant 23 (2008), 3479–3484.
63. 63 Maniatis, T., Fistch, E.F., Sambrook, J., Molecular Cloning. 1989, Cold Spring Harbor Laboratory Press, New York, NY.